New PBS behemoth arrives

Posted 6 February 2024 AM 

For the first time Vertex has taken first place in the annual top earners list, crushing 2023 with its triple-combination cystic fibrosis drug Trikafta earning a whopping $521.9 million pre-rebate on the R/PBS.

That represents an 80 per cent growth on what it earned for the full year 2022, although it only listed on 1 April of that year after an intense negotiation with the Department of Health.

To see the whole article, please login